Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. sclerotest

ScleroTest SIGNED

A rapid and cost-effective point-of-care diagnostic kit able to predict treatment response for appropriate Multiple Sclerosis management

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ScleroTest project word cloud

Explore the words cloud of the ScleroTest project. It provides you a very rough idea of what is the project "ScleroTest" about.

autoimmune    company    predictive    virus    inflammatory    acute    jc    disease    ing    patient    poc    adults    correct    worldwide    women    million    avenues    ca    perform    substantial    24    prompt    men    pcr    competition    plus    accurate    young    business    predicting    medicine    plan    patients    market    financial    chronic    bioithas    successful    launch    commercial    02    added    lack    profit    invasive    therapy    issue    mainly    33    gut    alternatives    therapeutic    therapies    unmet    annual    care    first    globally    multiple    sclerotest    absence    profiling    finalize    scalability    competitive    15    people    incidence    2026    58    personalized    ms    analyzing    net    cheaper    performance    fruitful    health    10    diagnostic    outcomes    secure    quick    foresees    immunomodulatory    central    public    fast    implantation    savings    feasibility    cagr    accumulated    25    biomarkers    prevalence    biotechnology    predict    lt    magnetic    tool    resonance    neurologists    times    technological    nervous    socioeconomic    opportunity    sclerosis    2022    18    biomarker    cure    point    properly    treatment    rapid    routine    diseases    microbiota    clinical   

Project "ScleroTest" data sheet

The following table provides information about the project.

Coordinator		 BIOITHAS SL 

Organization address
address: C/ MAESTRO JOAQUIN ZAPATER 6
city: ONIL ALICANTE
postcode: 3430
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Project website https://www.bioithas.com/h2020-sclerotest-project/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2019-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOITHAS SL ES (ONIL ALICANTE) coordinator 50˙000.00

Map

 Project objective

Multiple sclerosis (MS) is the most common chronic inflammatory disease of the central nervous system currently affecting about 2.5 million people worldwide (mainly young adults, three times more women than men). There is no cure and therapies do not properly work in all patients. Personalized medicine is needed but we lack predictive biomarkers for treatment response to secure prompt and early treatment and the best clinical outcomes for each patient. Thus, MS represents a major public health issue with a substantial socioeconomic impact (€15.5 B annual costs in Europe). Bioithas is a biotechnology company in the field of health developing new diagnostic and therapeutic targets for autoimmune and inflammatory diseases. In response to the unmet need, it is focused on developing the first-ever gut microbiota based biomarker for predicting MS treatment response. ScleroTest, a quick point-of-care (PoC) diagnostic tool, will allow immunomodulatory profiling of patients to predict treatment response. It is a non-invasive, accurate (PCR performance), rapid (results in <24 h) and cost-competitive test (€25 test, ca. 58 % cheaper than magnetic resonance and JC virus alternatives). ScleroTest implantation in routine practice will face current MS management problems resulting on added value for patients, neurologists and health systems by allowing fast and correct therapy choice, better clinical outcomes and cost-savings. ScleroTest scalability will also open new avenues for personalized therapy in other diseases. Due to ScleroTest´s cost-competitive features plus the absence of real competition, the increasing MS prevalence and incidence globally and the growing PoC market (CAGR 10%, €33 B by 2022), Bioithas foresees ScleroTest as a fruitful business opportunity (accumulated net profit ca. €18.02 M, 2022-2026). To secure the successful market launch, we will perform a feasibility study analyzing technological, commercial and financial aspects to finalize our business plan.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SCLEROTEST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SCLEROTEST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MACCO (2019)

Bring social robots into reality with the first real world leading bartender (MACCO)

Read More  

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.

Read More